Susan J. Schniepp - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Susan J. Schniepp


Susan J. Schniepp is a Pharmtech editorial advisory board (EAB) member

Susan J. Schniepp
Vice-President, OSO Biopharmaceuticals

Susan Schniepp has more than 28 years of experience in quality assurance for both the food and pharmaceutical industries. She has a degree in microbiology from Northern Illinois University and began her career in 1980 as a microbiologist in the food industry for Quaker Oats and M&M/Mars. In 1984, she began working for Searle Pharmaceuticals, and in 2000 she began working for Abbott Laboratories. In 2007, she formed her own consulting firm specializing in training, quality systems, technical writing, and standards interpretations. During her career in industry she had responsibilities for complaints, labeling, validation, documentation, and other quality systems, with a primary focus on establishing communications with compendial authorities.

Schniepp joined PDA in 2000 when she began working for Abbott Laboratories. She has presented at a number of PDA meetings and participated on a number of committees including the Joint Regulatory Conference Steering Committee, RAQC, Program Advisory Board, Technical Books Advisory Board, and The Membership Committee. In 2007, she was the recipient of PDA’s Distinguished Author Award for Understanding the United States Pharmacopeia and the National Formulary: Demystifying the Standards-Setting Process.

In addition to her PDA activities, Schniepp is chair of USP’s Monograph Development – Psychiatrics and Psychoactives Expert Committee for the 2005–2010 revision cycle, in addition to serving on the Council of Experts Executive Committee from 2005–2007. She is active in the Generic Pharmaceutical Association and founded both the Midwest and Western Compendial Discussion Groups.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here